The numbers coming out of Cohance Lifesciences have been hard to stomach. In FY26, revenue fell 13 per cent and adjusted EBITDA nearly halved. In the first quarter of FY27, things got worse: revenue dropped 23 per cent, the adjusted EBITDA margin sank to 2.2 per cent and the company slipped into a net loss. Yet at around ₹479 per share, the stock carries a market capitalisation of roughly ₹17,000 crore, a figure that assumes a lot of recovery is on the way.

That gap between what the business is earning today and what the market is paying for it is the question at the heart of this story: can a recovery justify the valuation?

This is an analysis of reported figures, not investment advice. Investors should do their own research or consult a registered adviser.

What the Latest Numbers Show

A note on the loss: Reports differ on the size of the net loss. Some filings-based reports put it at about ₹24.1 crore, and others at about ₹45 crore, and the EBITDA margin appears as 0.3 per cent on a reported basis and 2.2 per cent on an adjusted basis. The definitions differ, so it is worth checking the company’s filing before quoting a single figure.

Where Did the Revenue Go?

The decline was not spread evenly across the business.

• API+ segment: Revenue fell 10.4 per cent to about ₹265 crore, relatively resilient compared with the rest.
• Pharma CDMO: Revenue dropped 38.7 per cent to about ₹125 crore. The company attributes much of this to the timing of shipments.
• Specialty chemicals: Revenue fell about 34.7 per cent.

The contract development and manufacturing segment matters most for the investment case, because it is where the company has aimed for higher-margin, innovator-linked work. A sharp fall there explains much of the margin damage.

The NJ Bio Problem

The most uncomfortable detail is the gap between the standalone business and the consolidated one. The standalone business earned an adjusted EBITDA of about ₹33 crore on revenue of about ₹360 crore, a margin of 9.2 per cent. The US-based subsidiary NJ Bio, which makes antibody-drug conjugates and other complex biologics, recorded an adjusted EBITDA loss of about ₹32.8 crore, wiping out most of the standalone profit and pulling the consolidated margin down to 2.2 per cent.

Management has said that NJ Bio’s revenue was lower than expected. The subsidiary is central to the company’s push into new modalities such as ADCs, but it is also the clearest reason why the group’s profits have vanished.

What Is Management Promising?

Management has described Q1 FY27 as a “bottoming out” quarter, with a recovery expected in the second half of the year. Several things support that narrative:

• A new leader. Umang Vohra has taken over as Group CEO and expects the June quarter to mark the bottom.
• A restocking order. The company said it had secured a key restocking order, which it expects to help sales later in the year.
• A growing pipeline. It continues to advance its ADC and nucleic acid portfolios.
• Integration. The company expanded rapidly through acquisitions, including ZCL Chemicals, RA Chem Pharma and Avra Laboratories, which were combined with Suven Pharmaceuticals, and a period of consolidation is under way.
• A cushion. The balance sheet shows a net cash position, so the company is not in financial distress.

The Valuation Question

At a market capitalisation of about ₹17,000 crore, here is a rough sense of what is priced in. These are illustrative calculations, not forecasts.

• Sales multiple: Annualising Q1 revenue (about ₹422 crore × 4, or roughly ₹1,690 crore) gives a price-to-sales ratio of about 10 times.
• What would justify it: If revenue recovered to ₹2,200 crore at a 24 per cent EBITDA margin, EBITDA would be about ₹530 crore, which would put the valuation at roughly 32 times EBITDA. If revenue reached ₹2,600 crore at 28 per cent, EBITDA would be about ₹730 crore, or about 23 times.

These scenarios ignore net cash and minority interests and are only meant to show the scale of recovery that is being assumed. In other words, the market is paying today for margins and growth that the company has not recently delivered.

Why Might the Market Be Willing to Pay It?

Supporters of the stock would make several points.

1. A one-off trough. If the decline reflects shipment timing and de-stocking by customers, a rebound could be sharp.
2. Scarcity. India’s listed CDMO companies with exposure to high-value modalities are few, and investors have often paid a premium for that exposure.
3. Operating leverage. A recovery in revenue could lift margins quickly because many costs are fixed.
4. The balance sheet. Net cash gives management room to wait for the recovery.

What Are the Risks?

Sceptics would counter with their own list.

1. Execution risk. The recovery depends on a restocking order, shipment timing and NJ Bio’s turnaround, none of which is guaranteed.
2. Customer concentration and regulation. Contract manufacturers depend on a small number of large customers and on regulatory approvals, and delays can hit revenue sharply.
3. The subsidiary drag. Until NJ Bio breaks even, the consolidated margin will lag the standalone business.
4. A high bar. At the current price, even a decent recovery may already be reflected, which leaves little room for disappointment.
5. A long fall. The shares were trading around ₹918 in August 2025 and about ₹428 in August 2026, so investors who bought earlier have already seen heavy losses.

What to Watch Next

• The Q2 FY27 results, due in the coming weeks, which will be the first real test of the “bottoming out” claim.

• NJ Bio’s losses and revenue, and whether management gives a timeline for breakeven.
• CDMO order flow, including the restocking order and new ADC and oligonucleotide contracts.
• Standalone margins, which should be tracked against the 9.2 per cent in Q1 and the 20-plus per cent range earlier.
• Management commentary on the first margin milestone over the next two to three years.

The Bottom Line

Cohance’s story is one of a good standalone business, a loss-making acquisition-led expansion and a valuation that asks investors to look past both. A recovery is plausible, and management has laid out reasons for it. But the current price already assumes that the recovery will be strong and fast. The next two quarters will show whether the “bottoming out” call was right.

 

© Copyright 2026. All Rights Reserved. Powered by Vygr Media.